Eruptive melanocytic nevi (EMN) are rare multiple benign melanocytic nevi that develop within a few months. The phenomenon has been associated with a variety of dermatologic and systemic conditions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, epidermolysis bullosa, Addison disease, human immunodeficiency virus infection, and internal malignancy, among others. It also is commonly attributed to medications, particularly immunosuppressive and chemotherapeutic agents. We report a case of EMN in a 50-year-old man undergoing azathioprine therapy for antisynthetase syndrome.

Case Report
A 50-year-old man with a history of antisynthetase syndrome (positive for anti-Jo-1 polymyositis with interstitial lung disease) and sarcoidosis presented for evaluation of numerous new moles. The lesions had developed on the trunk, arms, legs, hands, and feet approximately 3 weeks after starting azathioprine 100 mg once daily for pulmonary and muscular involvement of antisynthetase syndrome. He denied any preceding cutaneous inflammation or sunburns. He had no personal or family history of skin cancer, and no family members had multiple nevi. Physical examination revealed 30 to 40 benign-appearing, 2- to 5-mm, hyperpigmented macules scattered on the medial aspect of the right foot (Figure 1A), left palm (Figure 1B), back, abdomen, chest, arms, and legs. A larger, somewhat asymmetric, irregularly bordered, and irregularly pigmented macule was noted on the left side of the upper back. A punch biopsy of the lesion revealed a benign, mildly atypical lentiginous compound nevus (Figure 2). Pathology confirmed that the lesions represented eruptive melanocytic nevi (EMN). The patient continued azathioprine therapy and was followed with regular full-body skin examinations. Mycophenolate mofetil was suggested as an alternative therapy, if clinically appropriate, though this change has not been made by the patient’s rheumatologists.

Comment
A PubMed search of articles indexed for MEDLINE using the search terms eruptive melanocytic nevi and azathioprine revealed 14 cases of EMN in the setting of azathioprine therapy, either during azathioprine monotherapy or in combination with other immunosuppressants, including systemic corticosteroids, biologics, and cyclosporine (Table). The majority of these cases occurred in renal transplant patients, with 3 additional cases reported in the setting of Crohn disease, and another in a patient with myasthenia gravis. Patients ranged in age from 8 to 42 years (mean age, 22 years), with lesions developing a few months to up to 7 years after starting therapy. When specified,
# Review of Eruptive Melanocytic Nevi Cases During Azathioprine Therapy

<table>
<thead>
<tr>
<th>Reference</th>
<th>(Year)</th>
<th>Age, y/Sex</th>
<th>Clinical Setting</th>
<th>Current Treatment</th>
<th>Characteristics of Lesions</th>
<th>Development of Lesions</th>
<th>Atypia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaibac et al¹</td>
<td>2003</td>
<td>10 patients: age range, 8–42 y (mean age [SD] at transplantation, 19.4 [7.4])</td>
<td>End-stage renal disease</td>
<td>Triple therapy with azathioprine 100 mg once daily, cyclosporine, and prednisolone</td>
<td>Crops of multiple nevi (generally &gt;100) on the trunk (all cases), as well as arm, leg, and soles in single patients</td>
<td>4 mo to 1 y after transplantation/initiation of triple therapy</td>
<td>2 patients with dysplastic nevi</td>
</tr>
<tr>
<td>Belloni et al²</td>
<td>2005</td>
<td>42/F</td>
<td>Crohn disease</td>
<td>Azathioprine 75 mg once daily</td>
<td>Nevi on the trunk, arms, and legs</td>
<td>5-y history of multiple nevi with the majority developing over a several-month period 3 y after starting azathioprine</td>
<td>Not specified</td>
</tr>
<tr>
<td>Bovenschen et al³</td>
<td>2006</td>
<td>24/F</td>
<td>Crohn disease</td>
<td>Azathioprine monotherapy or azathioprine and infliximab combination therapy</td>
<td>Multiple 2-mm nevi on the palms and soles</td>
<td>Few months after starting azathioprine</td>
<td>None</td>
</tr>
<tr>
<td>Braun et al⁴</td>
<td>2012</td>
<td>21/M</td>
<td>Myasthenia gravis</td>
<td>Azathioprine 125 mg once daily, dexamethasone 12 mg once daily</td>
<td>Homogenous, 1–3 mm, light to dark brown–pigmented macules on the trunk, palms, and soles</td>
<td>Over 3–4 mo, 2 y after starting treatment</td>
<td>Not specified</td>
</tr>
<tr>
<td>Wonders et al⁵</td>
<td>2012</td>
<td>22/F</td>
<td>Crohn disease</td>
<td>Azathioprine 100 mg once daily</td>
<td>Light brown to black-pigmented, smooth surfaced, 2-mm nevi (no change in size) on the bilateral soles</td>
<td>Discovered after 7 y of treatment; the macules were discovered incidentally on endoscopy</td>
<td>Typical lesions with no signs of malignant transformation</td>
</tr>
<tr>
<td>Current case</td>
<td></td>
<td>50/M</td>
<td>Antisynthetase syndrome (positive for anti–Jo-1 polymyositis with ILD) and sarcoidosis</td>
<td>Azathioprine 100 mg once daily</td>
<td>Black macules (2–5 mm with no change in size) on the back, abdomen, chest, arms, legs, left palm, medial aspect of the right foot</td>
<td>Over 4–6 wk, 3 wk after starting azathioprine</td>
<td>One 5-mm lesion on the left side of the upper back; biopsy showed a mildly atypical nevus</td>
</tr>
</tbody>
</table>

**Abbreviations:** F, female; M, male; ILD, interstitial lung disease.
Eruptive Melanocytic Nevi

Figure 1. Eruptive melanocytic nevi. Multiple hyperpigmented macules on the medial aspect of the right foot (A) and the left palm (B).

the reported lesions typically were small, ranging from 1 to 3 mm in size, and developed rapidly over a couple of months with a predilection for the palms, soles, and trunk. Although dysplastic nevi were described in only 2 patients, melanomas were not detected.

Various hypotheses have sought to explain the largely unknown etiology of EMN. Bovenschen et al suggested that immunocompromised patients have diminished immune surveillance in the skin, which allows for unchecked proliferation of melanocytes. Specifically, immune suppression may induce melanocyte-stimulating hormone or melanoma growth stimulatory activity, with composition-specific growth in skin at the palms and soles. The preferential growth on the palms and soles suggests that those regions may have special sensitivity to melanocyte-stimulating hormone. Woodhouse and Maytin postulated that the increased density of eccrine sweat glands in the palms and soles as well as the absence of pilosebaceous units and apocrine glands and plentiful Pacinian and Meissner corpuscles may allow for a unique response to circulating melanocytic growth factors. Another hypothesis suggests the presence of genetic factors that allow subclinical nests of nevus cells to form, which become clinical eruptions following chemotherapy or immunosuppressive therapy. Azathioprine also has been suggested to induce various transcription factors that play a critical role in differentiation and proliferation of melanocytic stem cells, which leads to the formation of nevi. Our case and others similar to it implore that further studies be done to determine the molecular mechanism driving this phenomenon and whether a specific genetic predisposition exists that lowers the threshold for rapid proliferation of melanocytes given an immunosuppressed status.

The risk for melanoma development in cases of EMN is unknown. Although our review of the literature did not reveal any melanomas reported in cases attributed to azathioprine, a theoretical risk exists given the established associations between melanoma and immunosuppression as well as increased numbers of nevi. Accordingly, these patients should be followed with regular skin examinations and biopsies of atypical-appearing lesions as indicated.

REFERENCES